217 related articles for article (PubMed ID: 7636545)
1. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan.
Yamamoto K; Hayashi Y; Hanada R; Kikuchi A; Ichikawa M; Tanimura M; Yoshioka S
J Clin Oncol; 1995 Aug; 13(8):2033-8. PubMed ID: 7636545
[TBL] [Abstract][Full Text] [Related]
2. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
3. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
4. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
5. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children.
Bessho F; Hashizume K; Nakajo T; Kamoshita S
J Pediatr; 1991 Aug; 119(2):237-41. PubMed ID: 1861208
[TBL] [Abstract][Full Text] [Related]
6. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
7. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
Takeda T; Shimada M; Iizuka S; Takasugi N
Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma of the urinary bladder, preclinically detected by mass screening.
Yokoyama S; Hirakawa H; Ueno S; Yabe H; Hiraoka N
Pediatrics; 1999 May; 103(5):e67. PubMed ID: 10224211
[TBL] [Abstract][Full Text] [Related]
9. Establishment of cut off values for vanillylmandelic acid and homovanillic acid in 24-hr urine accumulation during mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1987 Sep; 17(3):221-8. PubMed ID: 3669365
[TBL] [Abstract][Full Text] [Related]
10. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
[TBL] [Abstract][Full Text] [Related]
11. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
12. Serial measurement of urinary VMA and HVA levels from one infant: a study for neuroblastoma mass screening.
Sawada T; Numata K; Hirata S
J Pediatr Surg; 1992 Apr; 27(4):452-5. PubMed ID: 1522454
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous regression of localized neuroblastoma detected by mass screening.
Yamamoto K; Hanada R; Kikuchi A; Ichikawa M; Aihara T; Oguma E; Moritani T; Shimanuki Y; Tanimura M; Hayashi Y
J Clin Oncol; 1998 Apr; 16(4):1265-9. PubMed ID: 9552024
[TBL] [Abstract][Full Text] [Related]
14. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan.
Suita S; Zaizen Y; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Ueda K; Tasaka H; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Yano H; Akiyama H; Ikeda K
J Pediatr Surg; 1996 Apr; 31(4):555-8. PubMed ID: 8801312
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
16. Mass screening for neuroblastoma in Miyagi Prefecture.
Itano M; Morita S; Fujie H; Ohashi Y; Minegishi N; Minegishi M; Yamaguchi Y; Sato T; Tsuchiya S; Konno T
Tohoku J Exp Med; 1992 Oct; 168(2):137-9. PubMed ID: 1306297
[TBL] [Abstract][Full Text] [Related]
17. Seasonal variations in vanillylmandelic acid and homovanillic acid in infants' urine.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1987 Jun; 17(2):151-5. PubMed ID: 3613139
[TBL] [Abstract][Full Text] [Related]
18. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102
[TBL] [Abstract][Full Text] [Related]
19. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
20. Effects of mass screening on age-specific incidence of neuroblastoma.
Bessho F
Int J Cancer; 1996 Aug; 67(4):520-2. PubMed ID: 8759611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
